profit from every $100 of sales.
$0$100
Neogen
$11.60-0.60% today
+77.6% in 1 year
1-year low $5.411-year high $13.98
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Neogen sold, what it kept, and what it did with the cash.
Sales went from $527 million in 2022 to $895 million in 2025, with -$1.09 billion of profit last year.
SalesProfit
Neogen vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Neogen | No profit yet | ||
 Abbott Laboratories | 29.0× · Fair price | ||
 Medtronic | 27.1× · Fair price | ||
 Stryker | 37.4× · Expensive | ||
 Edwards Lifesciences | 56.7× · Expensive |
AI analysis
An AI analyst reads Neogen's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 527 | 822 | 924 | 895 | |
| 243 | 406 | 464 | 421 | |
| 59 | 38 | 59 | -2 | |
| 84 | 124 | 180 | -936 | |
| 48 | -23 | -9 | -1,092 | |
| 0.45 | -0.12 | -0.04 | -5.03 | |
| 46.1% | 49.4% | 50.2% | 47.1% | |
| 11.1% | 4.6% | 6.3% | -0.2% | |
| 9.2% | -2.8% | -1.0% | -122.1% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 993 | 4,554 | 4,549 | 3,444 |
| Cash | 44 | 163 | 171 | 129 |
| Total debt | – | 885 | 891 | 894 |
| Total liabilities | 106 | 1,420 | 1,405 | 1,373 |
| 887 | 3,134 | 3,144 | 2,071 | |
| 108 | 216 | 217 | 217 | |
| 5.4% | 0.7% | 1.2% | -28.3% | |
| 5.4% | -0.7% | -0.3% | -52.7% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 68 | 41 | 35 | 58 | |
| 24 | 66 | 111 | 105 | |
| 44 | -25 | -76 | -46 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 7 | 10 | 14 | 17 |
Valuation
- –
- 32.4×
- –
- 1.2×
- 2.8×
- –
- –
- -1.8%
- -43.1%
- 0.0%
Profitability
- 47.1%
- -0.2%
- -122.1%
- -51.2%
- 1.4%
- -6.5%
- -29.0%
- -18.1%
- -1.2%
- 2.3%
Growth
- +19.3%
- –
- +39.1%
- –
- +0.2%
Financial health
- –
- 0.38
- 0.0%
- 0.8×
- 3.82
- 2.84
- 0.26
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 37%of 959
Bottom 20%of 888
Top 29%of 889
Bottom 29%of 987
What analysts expect
- Average price target
- $11.00
- Range
- $10.00 – $12.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 9, 2026 | 0.09 | 0.04 | +125.0% |
| Jan 8, 2026 | 0.10 | 0.07 | +42.9% |
| Oct 9, 2025 | 0.04 | -0.07 | +154.1% |
| Jul 29, 2025 | 0.05 | 0.08 | −37.5% |
| Apr 9, 2025 | 0.10 | 0.13 | −23.1% |
| Jan 10, 2025 | 0.11 | 0.09 | +22.2% |
| Oct 10, 2024 | 0.07 | 0.09 | −17.6% |
| Jul 30, 2024 | 0.10 | 0.12 | −16.7% |
News
3 Reasons to sell NEOG and 1 stock to buy insteadYahoo Finance · Oct 24, 2026Neogen outlines FY 2027 revenue of $885M-$890M and adjusted EBITDA of $181M-$183M as Petrifilm transfer nears startSeeking Alpha · Oct 6, 2026Neogen Q1 2027 Earnings PreviewSeeking Alpha · Oct 5, 2026Neogen (NEOG): Buy, Sell, or Hold Post Q2 Earnings?Yahoo Finance · Sep 11, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
25No pass
Benjamin Graham
61Pass
Philip Fisher
41No pass
Peter Lynch
58No pass
Joel Greenblatt
0No pass
Charlie Munger
28No pass
Terry Smith
29No pass
Questions about Neogen
Is Neogen a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Neogen AI analysis
What does Neogen do?
Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through Food Safety and Animal Safety segments. It is in Medical Devices.
Does Neogen pay a dividend?
No. Neogen does not pay a dividend at the moment.
Is Neogen stock halal?
No. Neogen does not pass our halal screen: its debt is 35% of its market value, at or above the 33% limit. How we check
How has Neogen stock done over the past year?
Up 77.6% over the past twelve months, to $11.60. It traded between $5.41 and $13.98 and is 17.0% below its high.
Who are Neogen's competitors?
The largest listed companies in the same industry are Abbott Laboratories, Medtronic, Stryker and Edwards Lifesciences. The peers table on this page compares their profit, growth and price with Neogen's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.